Algocyte gives oncology teams earlier visibility into haematological toxicity, potentially reducing avoidable admissions and protecting treatment continuity.
Scheduled FBCs and outpatient appointments make monitoring intermittent, not regular.
Toxicity is identified after the patient has already deteriorated.
Repeated visits, blood draws and nursing time the service cannot spare.
Closer patient testing with Algocyte Proxima helps with risk stratification triggering alerts to surface deterioration earlier, so the team can intervene in clinic, not in an emergency setting.
Inside Health Hub
Longitudinal patient intelligence across regular FBC monitoring can keep patients on protocol, and gives the clinical team a defensible record of why decisions were made.
Meet Algocyte ProximaEarlier detection of haematological toxicity reduces emergency admissions.
Keeps regular FBC monitoring out of acute settings.
Replaces phone follow-up with longitudinal, structured clinical data.
Designed against digital, clinical safety and information-governance standards.
Book a 20-minute briefing with our team to see Algocyte in action.